AstraZeneca Q2 net profit declines 10%, revenue up 31%
AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...
snmjournals.org7h
Precision Oncology in Melanoma: Changing Practices
Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...